CD40L and IL-4 have recently been shown to inhibit NK cell activation against chronic lymphocytic leukaemia (CLL) cells via the HLA-E:NKG2A immune checkpoint axis. The gene discussed is KLRC1; the disease is B-cell chronic lymphocytic leukemia.